Elite Pharmaceuticals, Inc. (ELTP)
OTCMKTS: ELTP · Delayed Price · USD
0.154
-0.003 (-1.91%)
Nov 27, 2023, 3:59 PM EST - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Year | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 - 1998 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 34,155 | 32.26 | 25.38 | 17.99 | 7.57 | 7.46 | 9.64 | 12.5 | 5.02 | 4.6 | Upgrade
|
Revenue Growth (YoY) | 105767.55% | 27.11% | 41.05% | 137.76% | 1.47% | -22.61% | -22.89% | 149.21% | 8.99% | 35.19% | Upgrade
|
Cost of Revenue | 17,561 | 17.47 | 13.51 | 10.02 | 4.7 | 3.51 | 5.9 | 4.48 | 3.01 | 3.24 | Upgrade
|
Gross Profit | 16,594 | 14.8 | 11.87 | 7.98 | 2.87 | 3.95 | 3.74 | 8.01 | 2 | 1.37 | Upgrade
|
General & Administrative | 5,122 | 4.48 | 3.34 | 3.41 | 3.22 | 2.58 | 2.44 | 3.24 | 3.16 | 2.19 | Upgrade
|
Research & Development | 6,200 | 4.05 | 5.11 | 5.53 | 7.6 | 9.62 | 8.3 | 12.43 | 14.73 | 3.96 | Upgrade
|
Other Operating Expenses | 1,596 | 1.19 | 1.31 | 1.32 | 1.21 | 0.8 | 0.35 | 7.39 | 0.62 | 0.02 | Upgrade
|
Operating Expenses | 12,918 | 9.72 | 9.76 | 10.26 | 12.03 | 13 | 11.1 | 16.33 | 18.51 | 6.65 | Upgrade
|
Operating Income | 2,025 | 5.07 | 2.1 | -2.29 | -9.16 | -9.05 | -7.36 | -8.32 | -16.51 | -5.28 | Upgrade
|
Interest Income | 7.45 | 0 | 0 | 0.01 | 0.02 | 0.02 | 0.01 | 0 | 0 | 0 | Upgrade
|
Interest Expense | -1,112.71 | 0.19 | 0.26 | 0.36 | 0.37 | 0.34 | 0.24 | 0.28 | 0.29 | 0.9 | Upgrade
|
Other Expense / Income | -840.6 | -2.28 | -2.3 | -0.39 | 0.2 | -4.99 | -9.76 | -7.39 | -45.72 | 90.68 | Upgrade
|
Pretax Income | 3,986 | 6.3 | 4.14 | -2.24 | -9.96 | -4.72 | 1.94 | -1.2 | 28.93 | -96.87 | Upgrade
|
Income Tax | -424.03 | -1.74 | -0.94 | 0 | -0.43 | -0.71 | -1.63 | -0.52 | -0 | -0.29 | Upgrade
|
Net Income | 4,410 | 8.9 | 5.09 | -2.24 | -9.28 | -3.67 | 3.81 | -0.68 | 28.93 | -96.58 | Upgrade
|
Net Income Growth | 49459.23% | 74.87% | - | - | - | - | - | - | - | - | Upgrade
|
Shares Outstanding (Basic) | 1,013 | 1,011 | 943 | 832 | 814 | 796 | 839 | 674 | 591 | 463 | Upgrade
|
Shares Outstanding (Diluted) | 1,013 | 1,011 | 943 | 993 | 816 | 798 | 845 | 674 | 758 | 463 | Upgrade
|
Shares Change | 0.23% | 7.17% | -5.06% | 21.68% | 2.27% | -5.49% | 25.32% | -11.04% | 63.62% | -12.12% | Upgrade
|
EPS (Basic) | 4.35 | 0.01 | 0.01 | -0.00 | -0.01 | -0.00 | 0.03 | -0.00 | 0.05 | -0.21 | Upgrade
|
EPS (Diluted) | 4.35 | 0.01 | 0.00 | -0.00 | -0.01 | -0.00 | -0.01 | -0.00 | -0.02 | -0.21 | Upgrade
|
EPS Growth | 43400.00% | 143.90% | - | - | - | - | - | - | - | - | Upgrade
|
Free Cash Flow | -2.4 | 6.01 | 2.86 | -1.83 | -6.81 | -5.08 | -8.99 | -4.71 | -17.1 | -4.78 | Upgrade
|
Free Cash Flow Per Share | -0.00 | 0.01 | 0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | Upgrade
|
Gross Margin | 48.58% | 45.86% | 46.76% | 44.34% | 37.89% | 52.93% | 38.80% | 64.12% | 39.91% | 29.67% | Upgrade
|
Operating Margin | 5.93% | 15.72% | 8.29% | -12.70% | -121.01% | -121.35% | -76.32% | -66.54% | -329.14% | -114.83% | Upgrade
|
Profit Margin | 12.91% | 27.58% | 20.05% | -12.45% | -122.60% | -49.25% | 39.54% | -5.46% | 576.83% | -2098.83% | Upgrade
|
Free Cash Flow Margin | -0.01% | 18.63% | 11.28% | -10.16% | -90.00% | -68.16% | -93.27% | -37.72% | -340.96% | -103.82% | Upgrade
|
Effective Tax Rate | -10.64% | -27.54% | -22.77% | - | - | - | -83.84% | - | -0.01% | - | Upgrade
|
EBITDA | 3,289 | 6.51 | 3.63 | -0.76 | -7.88 | -8.04 | -6.63 | -0.26 | -15.89 | -4.76 | Upgrade
|
EBITDA Margin | 9.63% | 20.16% | 14.30% | -4.24% | -104.12% | -107.76% | -68.78% | -2.05% | -316.83% | -103.51% | Upgrade
|
Depreciation & Amortization | 1.34 | 1.43 | 1.52 | 1.51 | 1.26 | 1 | 0.71 | 0.67 | 0.58 | 0.45 | Upgrade
|
EBIT | 3,287 | 5.07 | 2.11 | -2.27 | -9.14 | -9.03 | -7.34 | -0.92 | -16.47 | -5.22 | Upgrade
|
EBIT Margin | 9.62% | 15.72% | 8.29% | -12.63% | -120.73% | -121.12% | -76.19% | -7.38% | -328.44% | -113.37% | Upgrade
|
Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.